CURIS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
CURIS, INC. (CRIS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 3.60% for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2023-11-02
- CURIS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 3.60%, a 111.76% increase year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-03-31 was 1.70%, a 142.86% increase year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 0.70%, a 58.82% decline year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-03-31 was 1.70%, a 34.62% decline year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 2.60%, a 13.33% decline from fiscal 2018.
- CURIS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 3.00%, a 42.86% increase from fiscal 2017.
- CURIS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.10%, a 10.53% increase from fiscal 2016.
- CURIS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 1.90%, a 0.00% change from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|---|
| 2023-09-30 | 3.60% 10-Q · filed 2023-11-02 | ||||
| 2023-06-30 | 3.60% 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | 3.60% 10-Q · filed 2023-05-04 | ||||
| 2022-09-30 | 2.90% 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | 2.50% 10-Q · filed 2023-08-03 | ||||
| 2022-03-31 | 1.70% 10-Q · filed 2023-05-04 | ||||
| 2021-09-30 | 1.40% 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | 1.40% 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | 0.70% 10-Q · filed 2022-05-05 | ||||
| 2020-09-30 | 1.70% 10-Q · filed 2021-11-09 | 170.00% 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | 1.70% 10-Q · filed 2021-08-03 | ||||
| 2020-03-31 | 1.70% 10-Q · filed 2021-05-12 | ||||
| 2019-12-31 | 2.60% 10-K · filed 2020-03-19 | ||||
| 2019-09-30 | 260.00% 10-Q · filed 2020-11-10 | 2.60% 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | 2.60% 10-Q · filed 2020-08-04 | ||||
| 2019-03-31 | 2.60% 10-Q · filed 2020-05-12 | ||||
| 2018-12-31 | 3.00% 10-K · filed 2020-03-19 | ||||
| 2018-09-30 | 2.80% 10-Q · filed 2019-11-05 | 3.00% 10-Q · filed 2018-11-01 | |||
| 2018-06-30 | 2.80% 10-Q · filed 2019-08-09 | ||||
| 2017-12-31 | 2.10% 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | 2.10% 10-Q · filed 2018-11-01 | ||||
| 2017-06-30 | 2.10% 10-Q · filed 2018-08-02 | ||||
| 2016-12-31 | 1.90% 10-K · filed 2018-03-08 | ||||
| 2016-09-30 | 1.80% 10-Q · filed 2017-11-07 | ||||
| 2016-06-30 | 1.80% 10-Q · filed 2017-08-03 | ||||
| 2016-03-31 | 1.80% 10-Q · filed 2017-05-04 | ||||
| 2015-12-31 | 1.90% 10-K · filed 2018-03-08 | ||||
| 2015-09-30 | 1.90% 10-Q · filed 2016-11-03 | ||||
| 2015-06-30 | 1.90% 10-Q · filed 2016-08-04 | ||||
| 2015-03-31 | 1.70% 10-Q · filed 2016-05-09 | ||||
| 2014-09-30 | 2.20% 10-Q · filed 2015-11-09 | ||||
| 2014-06-30 | 2.20% 10-Q · filed 2015-08-06 | ||||
| 2014-03-31 | 2.20% 10-Q · filed 2015-05-07 | ||||
| 2013-12-31 | 2.10% 10-K · filed 2016-02-29 | ||||
| 2012-12-31 | 1.20% 10-K · filed 2013-03-13 | ||||
| 2012-09-30 | 1.20% 10-Q · filed 2012-11-06 | ||||
| 2012-06-30 | 1.20% 10-Q · filed 2012-08-09 | ||||
| 2011-12-31 | 2.50% 10-K · filed 2013-03-13 | ||||
| 2011-09-30 | 2.50% 10-Q · filed 2012-11-06 | ||||
| 2011-06-30 | 2.50% 10-Q · filed 2012-08-09 | ||||
| 2010-12-31 | 2.80% 10-K · filed 2013-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |